|IBS and IBD In The News|
FDA Approves New Drug for Ulcerative ColitisSalix Pharmaceuticals July 24, 2000
A new drug, COLAZAL (balsalazide disodium) has been approved by the FDA for use in mild to moderate Ulcerative Colitis. The drug works by releasing the anti-inflammatory medication in the colon.
COLAZAL is a sulfa-free version of a 5-ASA. The active ingredient in sulfasalazine, a drug commonly used to treat ulcerative colitis, is sulfapyridine. The sulfapyridine is responsible for the side effects. COLAZAL uses a less toxic carrier molecule than sulfapyridine.
Currently COLAZAL is approved for up to 12 weeks of therapy. Side effects reported included abdominal pain and headaches. Salix expects to introduce COLAZAL into the United States in the first quarter of 2001. COLAZAL is currently available in Europe.
Salix Pharmaceuticals press release.
COLAZAL Home Page
Get notified when COLAZAL is available.